KMTS

ANALYST NOTE: KESTRA MEDICAL TECHNOLOGIES, LTD. (KMTS) DATE: 2026-06-13 SUBJECT: Structural Setup & Business Fundamentals Review

1. Structural Readiness

State: Context-only Conservative Entry: — Current Price: $19.93 Extension: — Breakout Level: — ATR Current: 7.2% (Very High)

Structural Assessment:

2. Thesis Layer

Thesis Classification: Tactical / Setup-Led Secular Exposure: None Named

At this date, KMTS does not carry a named macro or secular thesis (e.g., "AI-driven healthcare," "Demographic super-cycle"). The investment case is strictly TACTICAL, driven by the quality of the technical setup and the immediate business fundamentals. The conviction stack relies entirely on the structural integrity of the price action and the operational execution of the company's commercial strategy, rather than a broad market tailwind. No external macro thesis should be invented to support the position; the name must stand on its own setup quality and earnings trajectory.

3. Business Fundamentals

Company Overview: Kestra Medical Technologies, Ltd. is a commercial-stage medical device company operating in the Healthcare sector. The company's core business is the development and commercialization of the Cardiac Recovery System (CRS) platform.

Business Model: The company generates revenue primarily through the leasing of its flagship product, the ASSURE® Wearable Cardioverter Defibrillator (WCD).

• Revenue Mechanism: Lease payments are derived from contracted amounts based on reimbursement arrangements with third-party payors (Medicare, Medicaid, private commercial insurers) and patient co-payments.
• Product Scope: The CRS platform integrates cardiac monitoring, therapeutic intervention, digital health capabilities, and patient support services.

Operational Evidence (as of 2026-06-13):

• Revenue Growth: In the third quarter of fiscal 2026 (reported March 17, 2026), revenue reached $24.6 million, representing 63% growth year-over-year.
• Annual Context: For the fiscal year ended April 30, 2025, the company generated $59.8 million in revenue, a 115% increase from the prior year ($27.8 million).
• Unit Economics & Margins: The company reported a gross margin of 52.6% in Q3 2026, an improvement of 900 basis points year-over-year and 200 basis points sequentially. Management stated they are on a path to 70%+ gross margins over the next few years.
• Market Penetration: As of April 30, 2025, the ASSURE WCD had been worn by over 20,000 patients. Payor coverage is extensive, with over 285 million U.S. lives covered (approx. 90% of total available lives).
• Sales Force Expansion: The company ended 2025 with 100 active sales territories and was tracking toward a goal of 130 territories by the end of the fiscal year in April 2026.
• Guidance: Management increased full-year revenue guidance to $93 million, representing 55% growth compared to fiscal 2025.
• Product Validation: Management cited specific clinical utility, noting the system detected and delivered a lifesaving shock during the Christmas holidays of 2025.

4. Archetype and Conviction

Archetype: Growth Leader / Margin Inflector Valuation Context: The financial spine indicates the company is currently unprofitable on an EPS basis, with forward consensus estimates showing negative EPS for FY1 (-2.34) and FY2 (-2.19). This is consistent with a high-growth commercial-stage biotech/device company reinvesting heavily in sales expansion and R&D.

Conviction Stack Analysis:

• Thesis Strength: Low (Tactical only; no macro tailwind).
• Evidence Quality: High. The earnings transcript and SEC filings provide robust, quantitative data on revenue acceleration (115% YoY), margin expansion (52.6% and rising), and payor coverage (90% of lives).
• Structural Quality: Moderate to High. The business model is proven (leasing WCDs), and the path to profitability is defined by management (70% gross margin target).
• Rerating Potential: High, contingent on the company executing its guidance to $93M and demonstrating a clear path to GAAP profitability as margins expand toward the 70% target.

ATR Context: The current ATR of 7.2% is in the "Very High" bucket. While this offers potential for rapid price discovery upon a breakout, it also signals elevated risk of false moves or whipsaws. This volatility suggests that position sizing must be conservative until the structural breakout is confirmed.

5. Invalidations, Strengths, and Gaps

What Would Strengthen the Case:

• Margin Expansion: Continued sequential improvement in gross margins moving toward the 70% target.
• Guidance Beat: Exceeding the $93 million revenue guidance for the fiscal year.

What Would Invalidate the Case:

• Operational Setback: A significant reduction in sales territory count or a loss of major payor contracts (e.g., Medicare/Medicaid reimbursement rates).
• Margin Compression: A failure to maintain or improve gross margins despite revenue growth.

Evidence Gaps:

• Cash Position: The provided evidence does not explicitly state the current cash runway or burn rate, which is critical for a company with negative EPS.
• Competitive Landscape: While market share is implied to be high, specific data on competitor pricing or new entrants in the WCD space is not detailed in the provided snippets.
• International Progress: Management expects Western Europe expansion within three years, but no specific regulatory milestones or revenue contributions from this region are quantified yet.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: Revenue growth of 115% YoY for FY2025 and 63% in Q3 2026; Gross margin expansion to 52.6% with a management target of 70%+; Payor coverage of 285 million U.S. lives (90% of available lives). Key risks: Current negative EPS and unprofitability; Very high ATR (7.2%) indicating elevated volatility and potential for false breakouts; Dependence on a single product line (ASSURE WCD) for all revenue. Sizing hint: Reduce position size relative to standard growth setups due to high volatility and lack of confirmed breakout. Expected path: Management expects to reach 130 sales territories and achieve 70% gross margins over the next few years; revenue is guided to $93M for the current fiscal year. Expected horizon: 6 to 12 months for the setup to resolve into a confirmed trend or invalidation.